XNYS 10 Mar, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Robert J. Decker | VP Corporate Controller | Sale of securities on an exchange or to another person at price $ 247.87 per share. | 27 Feb 2026 | 4,075 | 23,682 (0%) | 0% | 247.9 | 1,010,070 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.67 per share. | 27 Feb 2026 | 4,075 | 27,757 (0%) | 0% | 115.7 | 471,355 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2026 | 4,075 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Sale of securities on an exchange or to another person at price $ 245.66 per share. | 20 Feb 2026 | 1,322 | 25,447 (0%) | 0% | 245.7 | 324,763 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Sale of securities on an exchange or to another person at price $ 243.00 per share. | 15 Feb 2026 | 2,283 | 10,658 (0%) | 0% | 243 | 554,769 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 1,349 | 1,349 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 1,847 | 3,692 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2026 | 49,382 | 49,382 | - | - | Employee Stock Options (Right to Buy) | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2026 | 3,546 | 3,546 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 21,721 | 21,721 | - | - | Employee Stock Options (Right to Buy) | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 29,927 | 59,854 | - | - | Employee Stock Options (Right to Buy) | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 1,349 | 12,007 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 15 Feb 2026 | 385 | 11,622 (0%) | 0% | 243.4 | 93,728 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 1,847 | 13,469 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 15 Feb 2026 | 528 | 12,941 (0%) | 0% | 243.5 | 128,542 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 157.92 per share. | 15 Feb 2026 | 21,721 | 34,662 (0%) | 0% | 157.9 | 3,430,180 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Sale of securities on an exchange or to another person at price $ 243.00 per share. | 15 Feb 2026 | 21,721 | 12,941 (0%) | 0% | 243 | 5,278,203 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 156.15 per share. | 15 Feb 2026 | 29,927 | 42,868 (0%) | 0% | 156.1 | 4,673,101 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Sale of securities on an exchange or to another person at price $ 243.00 per share. | 15 Feb 2026 | 29,927 | 12,941 (0%) | 0% | 243 | 7,272,261 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 9,459 | 9,459 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 131,734 | 131,734 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 4,505 | 9,008 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 3,682 | 3,682 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 73,054 | 0 | - | - | Performance Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 3,469 | 0 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 1,960 | 324,447 (0%) | 0% | 243.5 | 477,162 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 4,505 | 326,407 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 1,602 | 321,902 (0%) | 0% | 243.5 | 390,007 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 3,682 | 323,504 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 31,679 | 319,822 (0%) | 0% | 244.5 | 7,747,099 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 73,054 | 351,501 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 989 | 278,447 (0%) | 0% | 244.6 | 241,860 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 3,469 | 279,436 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 33,386 | 33,000 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 37,463 | 51,463 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 15,948 | 35,515 (0%) | 0% | 244.5 | 3,900,083 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,779 | 37,294 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 507 | 36,787 (0%) | 0% | 244.6 | 123,987 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,971 | 38,758 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 858 | 37,900 (0%) | 0% | 243.4 | 208,880 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,878 | 39,778 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 817 | 38,961 (0%) | 0% | 243.5 | 198,899 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.67 per share. | 13 Feb 2026 | 19,241 | 58,202 (0%) | 0% | 115.7 | 2,225,606 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 242.99 per share. | 13 Feb 2026 | 19,241 | 38,961 (0%) | 0% | 243.0 | 4,675,371 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 129.51 per share. | 13 Feb 2026 | 12,066 | 51,027 (0%) | 0% | 129.5 | 1,562,668 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 242.87 per share. | 13 Feb 2026 | 12,066 | 38,961 (0%) | 0% | 242.9 | 2,930,469 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 131.94 per share. | 13 Feb 2026 | 33,386 | 72,347 (0%) | 0% | 131.9 | 4,404,949 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 242.75 per share. | 13 Feb 2026 | 33,386 | 38,961 (0%) | 0% | 242.8 | 8,104,452 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 242.68 per share. | 13 Feb 2026 | 24,961 | 14,000 (0%) | 0% | 242.7 | 6,057,535 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 37,463 | 0 | - | - | Performance Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,779 | 0 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,971 | 1,971 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,878 | 3,754 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 53,793 | 53,793 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 3,863 | 3,863 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 19,241 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 12,066 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 164.62 per share. | 13 Feb 2026 | 20,521 | 46,219 (0%) | 0% | 164.6 | 3,378,167 | Common Stock |
| James D. Swanson | EVP, CIO | Sale of securities on an exchange or to another person at price $ 242.70 per share. | 13 Feb 2026 | 20,521 | 25,698 (0%) | 0% | 242.7 | 4,980,447 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 447 | 0 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 9,412 | 0 | - | - | Performance Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 19,368 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 22,191 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 492 | 491 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 709 | 1,418 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 19,449 | 19,449 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 1,397 | 1,397 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 20,521 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 447 | 19,298 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 143 | 19,155 (0%) | 0% | 244.6 | 34,971 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 9,412 | 28,567 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 3,547 | 25,020 (0%) | 0% | 244.6 | 867,419 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 165.89 per share. | 13 Feb 2026 | 19,368 | 44,388 (0%) | 0% | 165.9 | 3,212,958 | Common Stock |
| James D. Swanson | EVP, CIO | Sale of securities on an exchange or to another person at price $ 243.76 per share. | 13 Feb 2026 | 19,368 | 25,020 (0%) | 0% | 243.8 | 4,721,144 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 162.75 per share. | 13 Feb 2026 | 22,191 | 47,211 (0%) | 0% | 162.7 | 3,611,585 | Common Stock |
| James D. Swanson | EVP, CIO | Sale of securities on an exchange or to another person at price $ 243.71 per share. | 13 Feb 2026 | 22,191 | 25,020 (0%) | 0% | 243.7 | 5,408,169 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 492 | 25,512 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 214 | 25,298 (0%) | 0% | 243.4 | 52,098 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 709 | 26,007 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 309 | 25,698 (0%) | 0% | 243.4 | 75,226 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,847 | 3,692 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 54,869 | 54,869 | - | - | Employee Stock Options (Right to Buy) | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 3,940 | 3,940 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,302 | 179,315 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 409 | 178,906 (0%) | 0% | 244.6 | 100,021 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 27,412 | 206,318 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 13,547 | 192,771 (0%) | 0% | 244.6 | 3,312,919 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,594 | 194,365 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 816 | 193,549 (0%) | 0% | 243.4 | 198,655 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,847 | 195,396 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 945 | 194,451 (0%) | 0% | 243.4 | 230,060 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,302 | 0 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 27,412 | 0 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,594 | 1,594 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 325 | 114,287 (0%) | 0% | 243.4 | 79,121 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 651 | 106,606 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 217 | 106,389 (0%) | 0% | 244.5 | 53,067 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 13,706 | 120,095 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 6,414 | 113,681 (0%) | 0% | 244.6 | 1,568,544 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 606 | 114,287 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 310 | 113,977 (0%) | 0% | 243.5 | 75,470 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 635 | 114,612 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 651 | 0 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 13,706 | 0 | - | - | Performance Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 606 | 606 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 635 | 1,268 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 16,945 | 16,945 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 1,217 | 1,217 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 312 | 0 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 95 | 23,682 (0%) | 0% | 243.5 | 23,128 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 344 | 23,777 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 94 | 23,433 (0%) | 0% | 243.4 | 22,884 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 339 | 23,527 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 762 | 23,188 (0%) | 0% | 244.5 | 186,347 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 2,741 | 23,950 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 104 | 21,209 (0%) | 0% | 244.5 | 25,433 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 312 | 21,313 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 4,871 | 4,871 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 344 | 687 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 700 | 700 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 339 | 338 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 2,741 | 0 | - | - | Performance Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 1,034 | 1,034 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 492 | 491 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 8,594 | 0 | - | - | Performance Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 408 | 0 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Sale of securities on an exchange or to another person at price $ 243.39 per share. | 13 Feb 2026 | 6,197 | 23,003 (0%) | 0% | 243.4 | 1,508,288 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 270 | 29,200 (0%) | 0% | 243.5 | 65,732 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 526 | 29,470 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 252 | 28,944 (0%) | 0% | 243.4 | 61,349 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 492 | 29,196 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 3,748 | 28,704 (0%) | 0% | 244.5 | 916,573 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 8,594 | 32,452 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 144 | 23,858 (0%) | 0% | 244.5 | 35,215 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 526 | 1,050 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 14,405 | 14,405 | - | - | Employee Stock Options (Right to Buy) | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 408 | 24,002 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 27,076 | 27,076 | - | - | Employee Stock Options (Right to Buy) | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,063 | 2,126 | - | - | Restricted Share Units | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 961 | 961 | - | - | Restricted Share Units | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 13,706 | 0 | - | - | Performance Share Units | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 651 | 0 | - | - | Restricted Share Units | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 544 | 23,568 (0%) | 0% | 243.5 | 132,437 | Common Stock |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,063 | 24,112 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 492 | 23,049 (0%) | 0% | 243.4 | 119,777 | Common Stock |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 961 | 23,541 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 7,011 | 22,580 (0%) | 0% | 244.5 | 1,714,540 | Common Stock |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 13,706 | 29,591 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 314 | 15,885 (0%) | 0% | 244.6 | 76,789 | Common Stock |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 651 | 16,199 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 1,944 | 1,944 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 35,489 | 35,489 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 2,548 | 2,548 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 13,625 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 8,998 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 4,378 | 26,994 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.50 per share. | 13 Feb 2026 | 8 | 22,616 (0%) | 0% | 244.5 | 1,956 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 499 | 22,624 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,028 | 26,206 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 1,816 | 25,178 (0%) | 0% | 244.6 | 444,103 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.47 per share. | 13 Feb 2026 | 15 | 26,191 (0%) | 0% | 243.5 | 3,652 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,026 | 27,217 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 448 | 26,769 (0%) | 0% | 243.5 | 109,066 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.67 per share. | 13 Feb 2026 | 13,625 | 40,394 (0%) | 0% | 115.7 | 1,576,004 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Sale of securities on an exchange or to another person at price $ 244.20 per share. | 13 Feb 2026 | 13,625 | 26,769 (0%) | 0% | 244.2 | 3,327,225 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 129.51 per share. | 13 Feb 2026 | 8,998 | 35,767 (0%) | 0% | 129.5 | 1,165,331 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Sale of securities on an exchange or to another person at price $ 244.53 per share. | 13 Feb 2026 | 8,998 | 26,769 (0%) | 0% | 244.5 | 2,200,281 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 499 | 0 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 4,378 | 0 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,028 | 1,028 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 1,026 | 2,051 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 1,459 | 1,459 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 410 | 16,819 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 135 | 16,684 (0%) | 0% | 244.5 | 33,014 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 3,602 | 20,286 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.55 per share. | 13 Feb 2026 | 1,027 | 19,259 (0%) | 0% | 244.6 | 251,153 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 419 | 19,678 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 172 | 19,506 (0%) | 0% | 243.4 | 41,873 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 575 | 20,081 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.45 per share. | 13 Feb 2026 | 251 | 19,830 (0%) | 0% | 243.5 | 61,106 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 410 | 0 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 3,602 | 0 | - | - | Performance Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 419 | 418 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 575 | 1,150 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 20,322 | 20,322 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 73,054 | 73,054 | - | - | Performance Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 37,463 | 37,463 | - | - | Performance Share Units | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 9,412 | 9,412 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 27,412 | 27,412 | - | - | Performance Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 13,706 | 13,706 | - | - | Performance Share Units | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 2,741 | 2,741 | - | - | Performance Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 8,594 | 8,594 | - | - | Performance Share Units | |
| Elizabeth Forminard | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 13,706 | 13,706 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 4,378 | 4,378 | - | - | Performance Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 3,602 | 3,602 | - | - | Performance Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 06 Feb 2026 | 38,945 | 133,225 (0%) | 0% | 101.9 | 3,967,327 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 38,945 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.99 per share. | 06 Feb 2026 | 27,270 | 105,955 (0%) | 0% | 240.0 | 6,544,527 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 06 Feb 2026 | 5,625 | 19,744 (0%) | 0% | 101.9 | 573,019 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.99 per share. | 06 Feb 2026 | 3,335 | 16,409 (0%) | 0% | 240.0 | 800,367 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 5,625 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 15,571 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 06 Feb 2026 | 15,571 | 32,460 (0%) | 0% | 101.9 | 1,586,218 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.99 per share. | 06 Feb 2026 | 10,335 | 22,125 (0%) | 0% | 240.0 | 2,480,297 | Common Stock |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 129.51 per share. | 05 Feb 2026 | 8,921 | 21,774 (0%) | 0% | 129.5 | 1,155,359 | Common Stock |
| Elizabeth Forminard | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.90 per share. | 05 Feb 2026 | 6,226 | 15,548 (0%) | 0% | 237.9 | 1,481,165 | Common Stock |
| Elizabeth Forminard | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2026 | 8,921 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Sale of securities on an exchange or to another person at price $ 220.99 per share. | 26 Jan 2026 | 51,218 | 79,634 (0%) | 0% | 221.0 | 11,318,461 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Sale of securities on an exchange or to another person at price $ 221.48 per share. | 26 Jan 2026 | 48,782 | 30,852 (0%) | 0% | 221.5 | 10,804,432 | Common Stock |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 247 | 14,153 | - | - | Deferred Share Units | |
| Daniel Eduardo Pinto | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 154 | 331 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 185 | 5,058 | - | - | Deferred Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2025 | 21,721 | 43,442 | - | - | Employee Stock Options (Right to Buy) | |
| John C. Reed | EVP, Innovative Medicine, R&D | Sale of securities on an exchange or to another person at price $ 192.71 per share. | 17 Oct 2025 | 21,721 | 10,658 (0%) | 0% | 192.7 | 4,185,793 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 157.92 per share. | 17 Oct 2025 | 21,721 | 32,379 (0%) | 0% | 157.9 | 3,430,180 | Common Stock |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2025 | 280 | 13,816 | - | - | Deferred Share Units | |
| Daniel Eduardo Pinto | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2025 | 175 | 175 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2025 | 210 | 4,841 | - | - | Deferred Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2025 | 56,471 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Sale of securities on an exchange or to another person at price $ 177.81 per share. | 04 Sep 2025 | 56,471 | 178,013 (0%) | 0% | 177.8 | 10,040,883 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 04 Sep 2025 | 56,471 | 234,484 (0%) | 0% | 101.9 | 5,752,701 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 177.20 per share. | 29 Aug 2025 | 9,570 | 12,853 (0%) | 0% | 177.2 | 1,695,804 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.67 per share. | 29 Aug 2025 | 11,521 | 22,423 (0%) | 0% | 115.7 | 1,332,634 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 11,521 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 22 Aug 2025 | 125,824 | 401,791 (0%) | 0% | 101.9 | 12,817,691 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2025 | 125,824 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Sale of securities on an exchange or to another person at price $ 179.21 per share. | 22 Aug 2025 | 125,824 | 275,967 (0%) | 0% | 179.2 | 22,548,655 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 176.91 per share. | 15 Aug 2025 | 16,820 | 14,000 (0%) | 0% | 176.9 | 2,975,571 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 16,820 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 15 Aug 2025 | 16,820 | 30,820 (0%) | 0% | 101.9 | 1,713,453 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Sale of securities on an exchange or to another person at price $ 163.55 per share. | 17 Jul 2025 | 19,137 | 10,658 (0%) | 0% | 163.5 | 3,129,830 | Common Stock |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 322 | 13,437 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 231 | 4,597 | - | - | Deferred Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 25,255 | 25,255 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.31 per share. | 01 May 2025 | 11,002 | 29,795 (0%) | 0% | 156.3 | 1,719,723 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 25,255 | 40,797 (0%) | 0% | 0 | Common Stock | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 13,006 | - | - | Deferred Share Units | |
| Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 4,265 | - | - | Deferred Share Units | |
| Hubert Joly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 7,986 | - | - | Deferred Share Units | |
| Mary C. Beckerle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 15,395 | - | - | Deferred Share Units | |
| Mark B. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 19,755 | - | - | Deferred Share Units | |
| Jennifer A. Doudna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 9,656 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 4,329 | - | - | Deferred Share Units | |
| Nadja Y. West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 6,572 | - | - | Deferred Share Units | |
| Mark A. Weinberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,316 | 10,737 | - | - | Deferred Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2025 | 130,852 | 130,852 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2025 | 130,852 | 275,967 (0%) | 0% | 0 | Common Stock | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 225 | 11,690 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 188 | 3,013 | - | - | Deferred Share Units | |
| Robert J. Decker | VP Corporate Controller | Sale of securities on an exchange or to another person at price $ 165.88 per share. | 25 Feb 2025 | 6,999 | 21,001 (0%) | 0% | 165.9 | 1,160,994 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 6,999 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 101.87 per share. | 25 Feb 2025 | 6,999 | 28,000 (0%) | 0% | 101.9 | 712,988 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 15 Feb 2025 | 385 | 15,542 (0%) | 0% | 156.2 | 60,118 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 15,927 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 2,698 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 13,513 | 13,513 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 219,020 | 219,020 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,632 | 5,632 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 91,277 | 91,277 | - | - | Employee Stock Options (Right to Buy) | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 2,127 | 2,127 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 34,476 | 34,476 | - | - | Employee Stock Options (Right to Buy) | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,903 | 1,903 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 30,841 | 30,841 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 8,357 | 8,357 | - | - | Employee Stock Options (Right to Buy) | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,031 | 1,031 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 25,538 | 25,538 | - | - | Employee Stock Options (Right to Buy) | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,576 | 1,576 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 3,189 | 3,189 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 51,688 | 51,688 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 49,878 | 49,878 | - | - | Employee Stock Options (Right to Buy) | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 3,077 | 3,077 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 27,951 | 27,951 | - | - | Employee Stock Options (Right to Buy) | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,725 | 1,725 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 2,806 | 0 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 14 Feb 2025 | 1,015 | 16,889 (0%) | 0% | 156.7 | 159,061 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 2,806 | 17,904 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 8,386 | 406,819 (0%) | 0% | 156.7 | 1,314,170 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 19,282 | 0 | - | - | Performance Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,682 | 7,364 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,053 | 0 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,470 | 3,469 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,470 | 392,498 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,053 | 396,041 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 1,510 | 390,988 (0%) | 0% | 155.3 | 234,443 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 2,198 | 393,843 (0%) | 0% | 156.7 | 344,449 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,682 | 397,525 (0%) | 0% | 0 | Common Stock | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 1,602 | 395,923 (0%) | 0% | 156.1 | 250,152 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 19,282 | 415,205 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,316 | 20,661 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,779 | 1,779 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 507 | 1,272 (0%) | 0% | 155.3 | 78,717 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,014 | 5,286 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 1,144 | 4,142 (0%) | 0% | 156.7 | 179,276 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,971 | 6,113 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,316 | 0 | - | - | Performance Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,971 | 3,942 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,014 | 0 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,779 | 1,779 | - | - | Restricted Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 768 | 5,345 (0%) | 0% | 156.1 | 119,923 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 6,661 | 14,000 (0%) | 0% | 156.7 | 1,043,845 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 983 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,961 | 0 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 447 | 447 | - | - | Restricted Share Units | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 889 | 18,849 (0%) | 0% | 156.7 | 139,315 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,118 | 19,738 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 141 | 16,620 (0%) | 0% | 156.1 | 22,017 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 16,761 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 558 | 16,269 (0%) | 0% | 156.7 | 87,444 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,961 | 16,827 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 447 | 15,018 (0%) | 0% | 0 | Common Stock | |
| James D. Swanson | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 152 | 14,866 (0%) | 0% | 155.3 | 23,600 | Common Stock |
| James D. Swanson | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,118 | 0 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,053 | 0 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,594 | 3,188 | - | - | Restricted Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,465 | 0 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,302 | 167,221 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 410 | 166,811 (0%) | 0% | 155.3 | 63,657 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,053 | 170,864 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 1,348 | 169,516 (0%) | 0% | 156.7 | 211,245 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,594 | 171,110 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 651 | 170,459 (0%) | 0% | 156.2 | 101,654 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,465 | 185,924 (0%) | 0% | 0 | Common Stock | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 7,911 | 178,013 (0%) | 0% | 156.7 | 1,239,733 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,302 | 1,302 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 1,212 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 0 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 651 | - | - | Restricted Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 89,602 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 223 | 89,379 (0%) | 0% | 155.3 | 34,623 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 90,909 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 480 | 90,429 (0%) | 0% | 156.7 | 75,221 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 91,036 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 200 | 90,836 (0%) | 0% | 156.2 | 31,230 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 96,673 (0%) | 0% | 0 | Common Stock | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 2,393 | 94,280 (0%) | 0% | 156.7 | 375,007 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 0 | - | - | Performance Share Units | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 372 | 21,001 (0%) | 0% | 156.7 | 58,296 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,351 | 21,373 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 339 | 20,116 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 254 | 19,777 (0%) | 0% | 156.7 | 39,804 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 850 | 20,031 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 104 | 19,181 (0%) | 0% | 155.3 | 16,147 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 312 | 19,285 (0%) | 0% | 0 | Common Stock | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 850 | 0 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 339 | 677 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,351 | 0 | - | - | Performance Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 312 | 312 | - | - | Restricted Share Units | |
| Robert J. Decker | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 94 | 20,022 (0%) | 0% | 156.1 | 14,678 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,830 | 0 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 997 | 23,594 (0%) | 0% | 156.7 | 156,240 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 2,910 | 24,591 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 158 | 21,681 (0%) | 0% | 156.2 | 24,672 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 21,839 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 574 | 21,347 (0%) | 0% | 156.7 | 89,952 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,830 | 21,921 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 151 | 20,091 (0%) | 0% | 155.3 | 23,444 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 408 | 20,242 (0%) | 0% | 0 | Common Stock | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 492 | 983 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 2,910 | 0 | - | - | Performance Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 408 | 408 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 464 | 10,902 (0%) | 0% | 156.7 | 72,713 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 8,991 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 215 | 8,776 (0%) | 0% | 155.3 | 33,381 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 851 | 9,627 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 267 | 9,360 (0%) | 0% | 156.7 | 41,842 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 961 | 10,321 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 307 | 10,014 (0%) | 0% | 156.1 | 47,938 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,352 | 11,366 (0%) | 0% | 0 | Common Stock | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 651 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 851 | 0 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 961 | 1,922 | - | - | Restricted Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,352 | 0 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,029 | 2,056 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,765 | 0 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 499 | 499 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Sale of securities on an exchange or to another person at price $ 156.15 per share. | 13 Feb 2025 | 403 | 15,098 (0%) | 0% | 156.1 | 62,928 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,029 | 15,501 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 639 | 14,472 (0%) | 0% | 156.7 | 100,138 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,765 | 15,111 (0%) | 0% | 0 | Common Stock | |
| Timothy Schmid | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 193 | 13,346 (0%) | 0% | 155.3 | 29,965 | Common Stock |
| Timothy Schmid | EVP, WW Chair, MedTech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 499 | 13,539 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,007 | 12,966 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 141 | 11,959 (0%) | 0% | 155.3 | 21,892 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 411 | 12,100 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,601 | 0 | - | - | Performance Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 419 | 837 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,007 | 0 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 411 | 410 | - | - | Restricted Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 457 | 14,119 (0%) | 0% | 156.7 | 71,616 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,601 | 14,576 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 120 | 12,975 (0%) | 0% | 156.2 | 18,738 | Common Stock |
| Kristen Mulholland | EVP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 419 | 13,095 (0%) | 0% | 0 | Common Stock | |
| Kristen Mulholland | EVP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 290 | 12,676 (0%) | 0% | 156.7 | 45,446 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 19,282 | 19,282 | - | - | Performance Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 15,316 | 15,316 | - | - | Performance Share Units | |
| James D. Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 3,118 | 3,118 | - | - | Performance Share Units | |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 15,465 | 15,465 | - | - | Performance Share Units | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 5,837 | 5,837 | - | - | Performance Share Units | |
| Robert J. Decker | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,351 | 1,351 | - | - | Performance Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 2,910 | 2,910 | - | - | Performance Share Units | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,352 | 1,352 | - | - | Performance Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 2,806 | 2,806 | - | - | Performance Share Units | |
| Kristen Mulholland | EVP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 1,601 | 1,601 | - | - | Performance Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 126,369 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 126,369 | 489,671 (0%) | 0% | 100.1 | 12,644,482 | Common Stock |
| Joaquin Duato | Director, CEO and Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 100,643 | 389,028 (0%) | 0% | 153.1 | 15,410,456 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Sale of securities on an exchange or to another person at price $ 153.89 per share. | 07 Feb 2025 | 13,015 | 0 (0%) | 0% | 153.9 | 2,002,878 | Common Stock |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 13,015 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Joseph J. Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 13,015 | 13,015 (0%) | 0% | 100.1 | 1,302,281 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 58,504 | 213,355 (0%) | 0% | 100.1 | 5,853,910 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 47,436 | 165,919 (0%) | 0% | 153.1 | 7,263,400 | Common Stock |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 58,504 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 32,762 | 115,027 (0%) | 0% | 100.1 | 3,278,166 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 26,076 | 88,951 (0%) | 0% | 153.1 | 3,992,757 | Common Stock |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 32,762 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Eugene A. Woods | Director | 31 Dec 2024 | 100 | 250 (0%) | 0% | 145.5 | 14,553 | Common Stock | |
| Mark A. Weinberger | Director | Purchase of securities on an exchange or from another person at price $ 147.22 per share. | 12 Dec 2024 | 1,000 | 1,000 (0%) | 0% | 147.2 | 147,220 | Common Stock |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 208 | 2,804 | - | - | Deferred Share Units | |
| Hewson Marillyn A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 334 | 11,380 | - | - | Deferred Share Units | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 302 | 10,954 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 188 | 2,574 | - | - | Deferred Share Units | |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 30 Aug 2024 | 5,635 | 24,608 (0%) | 0% | 100.1 | 563,838 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Sale of securities on an exchange or to another person at price $ 165.06 per share. | 30 Aug 2024 | 5,635 | 18,973 (0%) | 0% | 165.1 | 930,113 | Common Stock |
| Robert J. Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 5,635 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 9,809 | 0 | - | - | Restricted Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.16 per share. | 08 Jul 2024 | 5,018 | 19,834 (0%) | 0% | 147.2 | 738,449 | Common Stock |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 9,809 | 24,852 (0%) | 0% | 0 | Common Stock | |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 314 | 10,573 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 211 | 2,368 | - | - | Deferred Share Units | |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 22 May 2024 | 68,835 | 0 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 22 May 2024 | 68,835 | 68,835 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Wolk | Exec VP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 22 May 2024 | 55 | 68,835 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 53,510 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 11,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 22,561 (0%) | 0% | 0 | Common Stock | |
| John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 14,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 50,510 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 25,561 (0%) | 0% | 0 | Common Stock | |
| Anne M. Mulcahy | Director | 25 Apr 2024 | 1,385 | 21,470 | - | - | Deferred Share Units | ||
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 10,173 | - | - | Deferred Share Units | |
| Paula A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 2,858 | - | - | Deferred Share Units | |
| Hubert Joly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 6,464 | - | - | Deferred Share Units | |
| Mary C. Beckerle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 13,643 | - | - | Deferred Share Units | |
| Darius E. Adamczyk | Director | 25 Apr 2024 | 1,385 | 3,712 | - | - | Deferred Share Units | ||
| Mark B. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 17,867 | - | - | Deferred Share Units | |
| Jennifer A. Doudna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 8,081 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 2,139 | - | - | Deferred Share Units | |
| Y. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 5,093 | - | - | Deferred Share Units | |
| Mark A. Weinberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 9,129 | - | - | Deferred Share Units | |
| D. Scott Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 1,385 | 15,603 | - | - | Deferred Share Units | |
| Vanessa Broadhurst | EVP, Global Corp Affairs | Sale of securities on an exchange or to another person at price $ 162.16 per share. | 13 Mar 2024 | 8,891 | 15,043 (0%) | 0% | 162.2 | 1,441,765 | Common Stock |
| Marillyn A. Hewson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 234 | 8,787 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 491 | 491 | - | - | Deferred Share Units | |
| Eugene A. Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 261 | 753 | - | - | Deferred Share Units | |
| E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 29,275 | 29,275 | - | - | Employee Stock Options (Right to Buy) | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,475 | 1,475 | - | - | Restricted Share Units | |
| E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,819 | 1,819 | - | - | Restricted Share Units | |
| Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,782 | 4,782 | - | - | Restricted Share Units | |
| Schmid Timothy | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 49,658 | 49,658 | - | - | Employee Stock Options (Right to Buy) | |
| Decker J. Robert | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 8,175 | 8,175 | - | - | Employee Stock Options (Right to Buy) | |
| J. Wolk Joseph | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 5,913 | 5,913 | - | - | Restricted Share Units | |
| Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 76,981 | 76,981 | - | - | Employee Stock Options (Right to Buy) | |
| J. Joseph Wolk | Exec VP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 95,197 | 95,197 | - | - | Employee Stock Options (Right to Buy) | |
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 46,406 | 46,406 | - | - | Employee Stock Options (Right to Buy) | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 23,745 | 23,745 | - | - | Employee Stock Options (Right to Buy) | |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 40,551 | 40,551 | - | - | Employee Stock Options (Right to Buy) | |
| Duato Joaquin | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 177,816 | 177,816 | - | - | Employee Stock Options (Right to Buy) | |
| Hait William N. | EVP, Chief EI and Med Officer | 15 Feb 2024 | 2,155 | 2,155 | - | - | Restricted Share Units | ||
| Elizabeth Forminard | Executive VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,883 | 2,883 | - | - | Restricted Share Units | |
| John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 65,163 | 65,163 | - | - | Employee Stock Options (Right to Buy) | |
| C. John Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,048 | 4,048 | - | - | Restricted Share Units | |
| D. James Swanson | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 23,745 | 23,745 | - | - | Employee Stock Options (Right to Buy) | |
| J. Decker Robert | VP Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,016 | 1,016 | - | - | Restricted Share Units | |
| N. Hait William | EVP, Chief EI and Med Officer | 15 Feb 2024 | 34,696 | 34,696 | - | - | Employee Stock Options (Right to Buy) | ||
| James Swanson D. | EVP, CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,475 | 1,475 | - | - | Restricted Share Units | |
| Timothy Schmid | EVP, WW Chair, MedTech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 3,085 | 3,085 | - | - | Restricted Share Units | |
| Joaquin Duato | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 11,046 | 11,046 | - | - | Restricted Share Units | |
| Peter Fasolo M. | Exec VP, Chief HR Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,519 | 2,519 | - | - | Restricted Share Units | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 408 | 24,143 (0%) | 0% | 0 | Common Stock | |
| Robert Decker J. | VP Corporate Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 86 | 18,973 (0%) | 0% | 157.8 | 13,575 | Common Stock |
| J. Joseph Wolk | Exec VP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 1,780 | 69,663 (0%) | 0% | 0 | Common Stock | |
| Taubert L. Jennifer | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 666 | 154,851 (0%) | 0% | 157.8 | 105,128 | Common Stock |
| Elizabeth Forminard | Executive VP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 1,302 | - | - | Restricted Share Units | |
| Schmid Timothy | EVP, WW Chair, MedTech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 250 | 13,040 (0%) | 0% | 157.9 | 39,463 | Common Stock |
| Forminard Elizabeth | Executive VP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 236 | 8,340 (0%) | 0% | 157.9 | 37,253 | Common Stock |
| Wolk J. Joseph | Exec VP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 773 | 68,890 (0%) | 0% | 157.8 | 122,018 | Common Stock |
| E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 1,302 | - | - | Restricted Share Units | |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 408 | 816 | - | - | Restricted Share Units | |
| Peter Fasolo M. | Exec VP, Chief HR Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 474 | 112,076 (0%) | 0% | 157.9 | 74,821 | Common Stock |
| N. Hait William | See Remarks | 13 Feb 2024 | 834 | 39,074 (0%) | 0% | 0 | Common Stock | ||
| Swanson James D. | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 447 | 14,765 (0%) | 0% | 0 | Common Stock | |
| D. Swanson James | EVP, CIO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 447 | 894 | - | - | Restricted Share Units | |
| Fasolo Peter M. | Exec VP, Chief HR Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 925 | 112,550 (0%) | 0% | 0 | Common Stock | |
| N. William Hait | See Remarks | 13 Feb 2024 | 834 | 1,666 | - | - | Restricted Share Units | ||
| James Swanson D. | EVP, CIO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 195 | 14,570 (0%) | 0% | 157.9 | 30,781 | Common Stock |
| J. Robert Decker | VP Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 313 | 624 | - | - | Restricted Share Units |